ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
0/0

Antibody Screening Results for Anti-Nucleocapsid Antibodies Towards the Development of a SARS-CoV-2 Nucleocapsid Protein Antigen Detecting Lateral Flow Assay

preprint
submitted on 24.07.2020 and posted on 27.07.2020 by David Cate, Helen Hsieh, Veronika Glukhova, Joshua D Bishop, H Gleda Hermansky, Brianda Barrios-Lopez, Ben D Grant, Caitlin E Anderson, Ethan Spencer, Samantha Kuhn, Ryan Gallagher, Rafael Rivera, Crissa Bennett, Sam A Byrnes, John T Connelly, Puneet K Dewan, David S. Boyle, Bernhard H Weigl, Kevin P Nichols

The global COVID-19 pandemic has created an urgent demand for accurate rapid point of care diagnostic tests. Antigen-based assays are suitably inexpensive and can be rapidly mass-produced, but sufficiently accurate performance requires highly-optimized antibodies and assay conditions. An automated liquid handling system, customized to handle lateral flow immunoassay (LFA) arrays, was used for high-throughput antibody screening of anti-nucleocapsid antibodies that will perform optimally on an LFA. Six hundred seventy-three anti-nucleocapsid antibody pairs were tested as both capture and detection reagents with the goal of finding those pairs that have the greatest affinity for unique epitopes of the nucleocapsid protein of SARS-CoV-2 while also performing optimally in an LFA format. In contrast to traditional antibody screening methods (e.g. ELISA, bio-layer interferometry), the methods described here integrate real-time LFA reaction kinetics and binding directly on nitrocellulose. We have identified several candidate antibody pairs that are suitable for further development of an LFA for SARS-CoV-2.

Funding

Funding provided by The Global Good Fund and Global Health Labs, a nonprofit organization created by Gates Ventures and the Gates Foundation to develop innovative solutions to address unmet needs in primary health care centers and the last mile.

History

Email Address of Submitting Author

kevin.nichols@ghlabs.org

Institution

Global Health Labs

Country

United States of America

ORCID For Submitting Author

0000-0002-0081-9249

Declaration of Conflict of Interest

No conflict of interest

Licence

Exports

Logo branding

Licence

Exports